The invention provides flow batteries and methods of using flow batteries that reduce loss of capacity. The loss of capacity may be mitigated by electrically oxidizing an organic species in the negolyte.
A compact laser-steering end effector includes a frame, at least two active mirrors, and a pair of actuators. The frame has a greatest dimension in a plane orthogonal to a longitudinal axis of no more than 13 mm, and the mirrors are mounted proximate to the distal end of the frame. The actuators are mounted to the frame and configured to respectively change the tilt of the active mirrors relative to the frame. A pathway is provided through the frame to deliver a laser beam to the mirrors, and wherein the mirrors are positioned and configurable via the actuators to reflect the laser beam off of each mirror en route to an external target.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
Disclosed herein is article includes a polymer layer under an external force causing the polymer layer to be under a first compressive mechanical stress; and a lubricating liquid within the polymer layer, the lubricating liquid being at a concentration within the polymer layer such that the lubricating liquid forms a stable overlayer over the surface of the polymer layer when the polymer layer is under the external force and the lubricating liquid does not form the stable overlayer over the surface of the polymer layer when the polymer layer is not under compressive stress.
This disclosure provides a system for generating liquid motion using a first electrode, second electrode, reservoir including a liquid electrolyte, and magnet. The combination of electrochemical and magnetic fields results in liquid motion that can be used for a variety of purposes.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Articles and devices comprising fluorinated polymers, as well as methods of preparing fluorinated polymers, are generally described. In some cases, such fluorinated elastomers can be used for sensing neural activity, e.g., by encapsulating electronic circuits, or other applications. Furthermore, according to certain embodiments, polymers can, surprisingly, be directly deposited onto layers comprising low molecular weight fluorinated polymers, e.g., without swelling in the presence of certain solvents. Some embodiments are generally directed to devices and methods for treating fluorinated polymers and subsequently depositing material onto the treated fluorinated polymers. This may allow the fabrication and patterning of multilayered articles comprising fluorinated elastomers.
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
7.
HARVESTING ELECTROSTATICS TO PERFORM CHEMICAL REACTIONS
The present application is directed to methods and systems for using contact electrification as an energy supply to do useful chemistry. In accordance with one aspect, the disclosed method stores such energy in chemical forms (e.g., ionization of polymeric materials) and transports it to the point of use. This energy can either be released at high voltage by building up excess charge in a capacitor (to do plasma chemistry or chemical biology) or low voltage by processing the charge directly (to do electrochemistry or form useful products).
Quantum reservoir computation is provided. A first feature vector is determined from input data. A plurality of qubits is configured in an initial configuration according to the first feature vector, wherein a detuning, Rabi frequency, phase, and/or position of each of the plurality of qubits is determined by a respective one of the values of the first feature vector. The plurality of qubits is evolved for a first time. The plurality of qubits is measured to obtain first measurements after the first time. The plurality of qubits is returned to the initial configuration. The plurality of qubits is evolved for a second time. The plurality of qubits is measured to obtain second measurements after the second time. A second feature vector is determined from the first and second measurements. The second feature vector is provided to a decoder and a characteristic of the input data is obtained therefrom.
Some aspects of this disclosure provide methods for phage-assisted continuous evolution (PACE) of proteases. Some aspects of this invention provide methods for evaluating and selecting protease inhibitors based on the likelihood of the emergence of resistant proteases as determined by the protease PACE methods provided herein. Some aspects of this disclosure provide strategies, methods, and reagents for protease PACE, including fusion proteins for translating a desired protease activity into a selective advantage for phage particles encoding a protease exhibiting such an activity and improved mutagenesis-promoting expression constructs. Evolved proteases that recognize target cleavage sites which differ from their canonical cleavage site are also provided herein.
Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
Chimeric small molecules comprising an immunogenic display moiety and methods of using the chimeric small molecules to label proteins with the immunogenic display moiety for MHC display on the surface of a cell or to label cell surface proteins with the immunogenic display moiety for display on the surface of a cell, thereby inducing an immune response.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
12.
SOFT ORGANIC SALTS FOR BAROCALORIC HEAT TRANSFER AND STORAGE
The invention provides methods, compositions, and systems for barocaloric applications such as cooling, heating, and energy storage using soft organic salts.
The disclosure provides a method for detecting a target analyte in a biological sample including contacting the sample with one or more probe sets each comprising a primary probe and a linker, contacting the sample with an initiator sequence, contacting the sample with a plurality of fluorescent DNA hairpins, wherein the probe binds the target molecule, the linker connects the probe to the initiator sequence, and wherein the initiator sequence nucleates with the cognate hairpin and triggers self-assembly of tethered fluorescent amplification polymers, and detecting the target molecule by measuring fluorescent signal of the sample.
Disclosed herein are GDF11 variant polypeptides. Also disclosed herein are methods for increasing GDF11 protein levels in a subject by administering a GDF11 variant polypeptide.
The present invention provides a new type of alpha-helix nucleating cross-link (“staple”) formed by olefin metathesis of a proline derivative with an alkenyl side chain and another amino acid derivative with an alkenyl side chain. The proline derivatives as described herein have been found to be strong nucleators of alpha-helix formation. The invention also provides moieties for shielding the free amide N—H's at the N-terminus of an alpha-helix, thereby further stabilizing the helix. The proline derivatives, precursors prior to cross-linking, and the cross-linked peptides are provided as well as methods of using and preparing these compounds and peptides.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
A method of transferring energy comprising: applying energy to a composition comprising a pressure transmitting medium in contact with a pressure sensitive material, wherein the composition is compressed; decompressing the composition to allow the pressure sensitive material to undergo an exothermic phase transition; and removing the energy from the composition; wherein the pressure sensitive material undergoes a reversible phase transition upon application of pressure.
C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
F25D 9/00 - Devices not associated with refrigerating machinery and not covered by groups ; Combinations of devices covered by two or more of the groups
F28D 20/02 - Heat storage plants or apparatus in general; Regenerative heat-exchange apparatus not covered by groups or using latent heat
The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound and methods of identifying one or more targets using such a compound.
C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
18.
Metasurface Optical Components for Altering Incident Light
Multi-wavelength light is directed to an optic including a substrate and metasurface optical components deposited on a surface of the substrate. The metasurface optical components comprise a pattern of silicon dielectric resonators with nonperiodic gap distances between adjacent dielectric resonators. Incident light directed to the metasurface optical components is scattered and phase-shifted by the configuration of the gap distances and the widths and thicknesses of the dielectric resonators. Each dielectric resonator has a rectangular cross-section such that a first phase shift is imparted for a transverse-electric (TE) component of the incident light and a second phase shift is imparted for a transverse-magnetic (TM) component of the incident light.
H01Q 15/10 - Refracting or diffracting devices, e.g. lens, prism comprising three-dimensional array of impedance discontinuities, e.g. holes in conductive surfaces or conductive discs forming artificial dielectric
HTTFXNFXN genes. Complexes, compositions, and systems comprising a prime editor and any of the pegRNAs disclosed herein are also provided by the present disclosure. The present disclosure further provides polynucleotides, vectors, AAVs, cells, compositions, and kits. Methods of treating Huntington' s disease and Friedreich's ataxia, as well as uses of the compositions, pegRNAs, and systems described herein, are also provided herein.
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the same. Further described herein are immune cells differentiated using stromal -free methods and compositions comprising such immune cells. In some embodiments, the immune cells can be genetically modified. In some embodiments, the immune cells or compositions comprising said immune cells can be administered to a patient as a cellular replacement therapy to treat a condition.
The present disclosure relates to pharmaceutical compositions comprising engineered macrophages and methods of use thereof. In some aspects, the present disclosure relates to engineered macrophages derived from pluripotent stem cells. In some embodiments, the stem cell genome is edited to knock-out (e g., SIRPa) and/or knock-in (e g., CAR) genes of interest prior to differentiation into macrophages. In some embodiments, engineered macrophages lack a SIRPa receptor. In some embodiments, the engineered macrophages express chimeric antigen receptors that induce and/or enhance phagocytosis. Alternatively, or additionally, in some embodiments, macrophages are engineered with combinatorial antigen-sensing circuits to improve tumor recognition and phagocytosis. Other aspects of the disclosure relate to methods of treating cancer in a subject and/or methods of enhancing cancer cell phagocytosis.
The technology described herein is directed to compositions comprising antibodies and antibody reagent that binds specifically to Mfsd2A and method of using such compositions, e.g., to increase blood-brain barrier permeability in therapeutic methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The technology described herein is directed to engineered chemoautotrophic bacteria and methods of producing triacylglycerides. Also described herein are systems or bioreactors comprising said engineered bacteria.
Forced expression of a handful of transcription factors (TFs) can induce conversion between cell identities; however, the extent to which TFs can alter cell identity has not been systematic ally assessed. Here, we assembled a “human TFome,” a comprehensive expression library of 1,578 human TF clones with fall coverage of the major TF families. By systematically screening the human TFome, we identified many individual TFs that induce loss of human-induced-pluripotent-stem-cell (hiPSC) identity, suggesting a pervasive ability for TFs to alter cell identity. Using large-scale computational cell type classification trained on thousands of tissue expression pantiles, we identified cell types generated by these TFs with high efficiency and speed, without additional selections or mechanical perturbations. TF expression in adult human tissues only correlated with some of the cell lineage generated, suggesting more complexity than observation studies can explain.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
26.
METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS
The technology described herein is directed to adjuvants comprising ionic liquids, as well as compositions and methods utilizing or comprising such adjuvants.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
28.
BASE EDITING METHODS AND COMPOSITIONS FOR TREATING TRIPLET REPEAT DISORDERS
The present disclosure provides compositions and methods useful in the treatment of trinucleotide repeat disorders, including Huntington's disease and Friedreich's ataxia. The present disclosure also provides gRNAs designed to target the HTT or FXN genes. Complexes comprising a base editor and any of the gRNAs disclosed herein are also provided by the present disclosure. The present disclosure further provides polynucleotides, vectors, cells, compositions, and kits. Methods of treating Huntington's disease and Friedreich's ataxia are also provided herein.
The present invention generally relates to systems and methods for imaging or determining nucleic acids or other desired targets, for instance, within cells or tissues. In one aspect, a sample is exposed to a plurality of nucleic acid probes that are determined within the sample. In some cases, however, background fluorescence or off-target binding may make it more difficult to determine properly bound nucleic acid probes. Accordingly, other components of the samples that may be contributing to the background, such as proteins, lipids, and/or other non-targets, may be “cleared” from the sample to improve determination. However, in certain embodiments, nucleic acids or other desired targets may be prevented from also being cleared, e.g., using polymers or gels within the sample. Other aspects are generally directed to compositions or kits involving such systems, methods of using such systems, or the like.
Provided herein are systems, compositions, and methods of introducing protective and/or loss-of-function variants of CCR5 and CCR2. Variants may be introduced using a CRISPR/Cas9-based nucleobase editor or other guide nucleotide sequence-programmable DNA binding protein domain-based fusion protein described herein. Further provided herein are compositions and methods of preventing and treating conditions related to HIV infection and progression as well as to AIDS.
The embodiments of the invention described herein relate to systems and methods for culturing and/or maintaining intestinal cells, tissues and/or organoids in vitro. The cells, tissues and/or organoids cultured according to the methods and systems described herein can mimic or reproduce natural intestinal epithelial structures and behavior as well as support co-culture of intestinal microflora.
INTERCONNECTION LAYER STRUCTURES INCLUDING TWO-DIMENSIONAL (2D) MATERIAL, ELECTRONIC DEVICES INCLUDING INTERCONNECTION LAYER STRUCTURES, AND ELECTRONIC APPARATUSES INCLUDING ELECTRONIC DEVICES
An interconnection layer structure including a two-dimensional (2D) material, an electronic device including the interconnection layer structure, and an electronic apparatus including the electronic device are disclosed. The interconnection layer structure may include a first interconnection layer, and a work function modulation layer directly on one surface of the first interconnection layer. The first interconnection layer may include a metal layer, and the work function modulation layer may be a two-dimensional (2D) material layer that includes ruthenium (Ru).
H01L 23/532 - Arrangements for conducting electric current within the device in operation from one component to another including external interconnections consisting of a multilayer structure of conductive and insulating layers inseparably formed on the semiconductor body characterised by the materials
H01L 23/528 - Layout of the interconnection structure
A semiconductor device may include a two-dimensional (2D) material having a semiconductor characteristic, a conductive layer on a first surface of the 2D material layer, and an alignment adjusting layer on a second surface of the 2D material layer. The second surface may be different from the first surface. The alignment adjusting layer may adjust an energy-band alignment between the 2D material layer and the conductive layer.
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
H01L 29/24 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only inorganic semiconductor materials not provided for in groups , , or
The present invention provides vaccine compositions and methods of producing such compositions. Other embodiments of the invention include methods of treating a pathogen infection, methods of vaccinating a subject against a pathogen infection, and methods for treating an antibiotic-resistance bacterial infection in a subject in need thereof. In further embodiments, the invention includes methods of decreasing the level of a pathogen in a subject having a pathogen infection, methods of increasing the surviving rate of a subject having a pathogen infection, methods of reducing the level of pain associated with a pathogen infection, and methods of reducing the level of distress associated with a pathogen infection in a subject in need thereof. Novel scaffold compositions and opsonin-bound or lectin-bound pathogen compositions, and uses thereof, are also provided herein.
Systems and methods, and associated compositions, for producing large libraries of nucleic acids are generally described. The methods provided herein may be used to produce libraries that include mutations that are unlikely in conventional library generation techniques, and may facilitate the production of large libraries with reduced processing demands.
36.
SYSTEMS AND METHODS FOR SCREENING OF LARGE GENE LIBRARIES
Library screening is an important analytic tool for identifying functional nucleic acids or proteins. In some aspects, droplet-based systems and methods for library screening are provided. The systems and methods may include steps of sorting droplets based on activity, amplifying nucleic acids of "activity droplets" having high activity, and separating nucleic acids from the activity droplets into new droplets. The steps may be iterated, such that activity droplets from successive iterations tend to include fewer nucleic acids. Such approaches may facilitate identification of active nucleic acids, or of nucleic acids encoding active proteins.
Described herein are compositions and methods of CRISPR effector system mediated detection of targets, including, but not limited to viral targets. Also described herein are devices and kits for carrying out the CRISPR effector system mediated nucleic acid detection assays.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
Described herein are compositions and methods for generating a viable cell that expresses at least one or more woolly mammoth genes. Also described herein are compositions and methods for generating an embryo, blastula, oocyte, or non-human organism that expresses one or more woolly mammoth genes.
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing educational scholarships and fellowships in support of scholars, scientists, artists, and writers working in a wide range of academic disciplines, professions, and creative arts Educational services, namely, developing, arranging, and conducting educational conferences and lectures in a wide range of academic disciplines, professions, and creative arts Scholarly research in a wide range of academic disciplines, professions, and creative arts, namely, in the fields of fine arts, science, humanities and social science
42.
VALVED NOZZLE WITH A COMPENSATOR AND MASSIVELY PARALLEL 3D PRINTING SYSTEM
In one aspect, the present disclosure provides a nozzle for a 3D printing system. The nozzle may include a flowpath with a material inlet and a material outlet. The nozzle may further include a valve in fluid communication with the flowpath between the material inlet and the material outlet, where the valve includes a closed state and an open state, where in the closed state the valve obstructs the flowpath between the material inlet and the material outlet, and where in the open state the material inlet is in fluid communication with the material outlet. The nozzle may further include a compensator in fluid communication with the flowpath, where the compensator includes a contracted state associated with the open state of the valve and an expanded state associated with the closed state of the valve.
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
B33Y 40/00 - Auxiliary operations or equipment, e.g. for material handling
43.
SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
An optical component can include a substrate. The optical component can include a metasurface disposed on the substrate. The metasurface can include one or more linearly birefringent elements. A spatially-varying Jones matrix and a far-field of the metasurface can define a transfer function of the metasurface configured to generate a controlled response in the far-field according to polarization of light incident on the metasurface.
A particle alpha radiation sampler includes a scintillation cell, a Geiger counter for measuring the incidence of particle alpha radiation on the scintillation cell, a vessel defining a chamber, at least one inertial impactor, a filter, and a vacuum pump. The scintillation cell is configured to receive alpha radiation passing through air in the chamber from particulate matter collected on the filter. The inertial impactor is configured to allow passage of particles only at or below an established size threshold into the chamber. The filter is configured to collect particulate matter from the air in the chamber drawn through the inertial impactor. Finally, the vacuum pump is configured to draw air flow through the filter from the chamber and to draw air flow through the inertial impactor into the chamber.
The present disclosure provides compositions, methods, kits and uses for regulating blood-Central Nervous System (blood-CNS) barrier permeability (e.g., increasing or decreasing blood-CNS barrier permeability) by regulating signaling between endothelial cell derived Cede 141 and Pacsin2 expressed in CNS endothelial cells.
Provided herein are methods of treating cancer in a subject, the method comprising administering to the subject an agent that increases or stabilizes the activity or expression of PIEZO 1.
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Provided herein are compounds that promote targeted degradation of IKZF1, IKZF2, GSPT1, and/or CKla, proteins whose activities are implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF1, IKZF2, GSPT1, and/or CKla in a subject or biologcial sample by administering a compound or composition described herein.
The technology described here is directed to a system and method of determining a bolus insulin dose for a person with diabetes to address prolonged hyperglycemia. A bolus insulin dose for the person is output from a jointly weighted zone model predictive control. The algorithm has a cost function that minimizes predicted glucose deviation from the upper zone weighted by a joint function of predicted glucose rate-of-change (ROC) and insulin-on-board (IOB). The asymmetric weighting gradually increases when glucose ROC and IOB were jointly low, independent of glucose magnitude, to limit hyperglycemia while aggressively reduces the weight for negative glucose ROC to avoid hypoglycemia.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
Dielectric elastomer actuators and methods of manufacturing thereof are generally described. The methods of manufacturing dielectric elastomer actuators comprise two independent steps: (1) depositing a conductive material on a plurality of portions of one or more carrier substrates to form a plurality of electrodes; and (2) transferring the plurality of electrodes to a plurality of elastomer layers to form dielectric elastomer actuators.
H10N 30/05 - Manufacture of multilayered piezoelectric or electrostrictive devices, or parts thereof, e.g. by stacking piezoelectric bodies and electrodes
H10N 30/20 - Piezoelectric or electrostrictive devices with electrical input and mechanical output, e.g. functioning as actuators or vibrators
H10N 30/50 - Piezoelectric or electrostrictive devices having a stacked or multilayer structure
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
H01B 1/20 - Conductive material dispersed in non-conductive organic material
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, providing online courses of instruction at the undergraduate, graduate and post-graduate level and distribution of course material in connection therewith
56.
DELIVERY OF THERAPEUTIC RNAS VIA ARRDC1-MEDIATED MICROVESICLES
Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
57.
ORGANOMIMETIC DEVICES AND METHODS OF USE AND MANUFACTURING THEREOF
An organomimetic device includes a microfluidic device that can be used to culture cells in its microfluidic channels. The organomimetic device can be part of dynamic system that can apply mechanical forces to the cells by modulating the microfluidic device and the flow of fluid through the microfluidic channels. The membrane in the organomimetic device can be modulated mechanically via pneumatic means and/or mechanical means. The organomimetic device can be manufactured by the fabrication of individual components separately, for example, as individual layers that can be subsequently laminated together.
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins further comprise a nuclear localization sequence (NLS), and/or an inhibitor of base repair, such as, a nuclease dead inosine specific nuclease (dISN).
Disclosed herein are 3-D neural tissue structures or “brain organoids” created from human pluripotent cells (e.g., stem cells) differentiated into neuronal cell types that include cortical and subcortical neuronal subtypes along with sensory cells. Also disclosed herein are methods for the in vitro generation of 3-D neural tissue structures capable of sensory perception, methods for generating a “brain organoid-machine interface” (BOMI), and methods for screening of molecular, cellular and network-level defects associated with complex mental diseases through use of patient-derived induced pluripotent stem cells.
Systems and methods for producing and using a body having a first structure defining a first chamber, a second structure defining a second chamber, a membrane located at an interface region between the first chamber and the second chamber to separate the first chamber from the second chamber. The first chamber comprises a first permeable matrix disposed therein and the first permeable matrix comprises at least one or a plurality of lumens each extending therethrough, which is optionally lined with at least one layer of cells. The second chamber can comprise cells cultured therein. The systems and methods described herein can be used for various applications, including, e.g., growth and/or differentiation of primary cells, and/or simulation of a microenvironment in living tissues and/or organs (to model physiology or disease states, and/or to identify therapeutic agents). The systems and methods can also permit co-cultures of two or more different cell types.
The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Aspects of the disclosure relate to Botulinum toxin X (BoNT X) protein variants. The variants provided herein have been evolved to cleave GTP cyclohydrolase 1 (GCH1). Some of the variants provided herein were evolved from a procaspase- 1 cleaving polypeptide. Further aspects of the disclosure relate to nucleic acids encoding the GCH1 cleaving polypeptides described herein and expression vectors comprising the nucleic acids, as well as host cells and fusion proteins comprising the GCH1 cleaving polypeptides described herein, and kits comprising the GCH1 polypeptides, fusion proteins, nucleic acids, expression vectors, or host cells described herein. Further aspects of the disclosure relate to methods of producing BoNT X variants and methods of using the BoNT X protein variants, for example, to reduce pain.
The present invention provides methods and compositions for treating cancers, as well as methods for increasing an immune response against a tumor, in a subject in need thereof by decreasing the expression and/or activity of Stub1 in an immune cell of the subject.
Genetic circuits that control transgene expression in response to pre-defined transcriptional cues would enable the development of smart therapeutics. The present disclosure relates to engineered programmable single-transcript RNA sensors in which adenosine deaminases acting on RNA (ADARs) autocatalytically convert trigger hybridization into a translational output. This system amplifies the signal from editing by endogenous ADAR through a positive feedback loop. Amplification is mediated by the expression of a hyperactive, minimal ADAR variant and its recruitment to the edit site via an orthogonal RNA targeting mechanism. This topology confers high dynamic range, low background, minimal off-target effects, and a small genetic footprint. The circuits and systems disclosed herein leverage an ability to detect single nucleotide polymorphisms and modulate translation in response to endogenous transcript levels in mammalian cells.
Genetic circuits that control transgene expression in response to pre-defined transcriptional cues would enable the development of smart therapeutics. The present disclosure relates to engineered programmable single-transcript RNA sensors in which adenosine deaminases acting on RNA (ADARs) autocatalytically convert trigger hybridization into a translational output. This system amplifies the signal from editing by endogenous ADAR through a positive feedback loop. Amplification is mediated by the expression of a hyperactive, minimal ADAR variant and its recruitment to the edit site via an orthogonal RNA targeting mechanism. This topology confers high dynamic range, low background, minimal off-target effects, and a small genetic footprint. The circuits and systems disclosed herein leverage an ability to detect single nucleotide polymorphisms and modulate translation in response to endogenous transcript levels in mammalian cells.
G06K 19/02 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the selection of materials, e.g. to avoid wear during transport through the machine
G06K 19/00 - Record carriers for use with machines and with at least a part designed to carry digital markings
The present invention relates to systems, compositions, and methods for altering nucleic acids, such as at a single position (e.g., A/T to G/C or G/C to A/T; in a gene with disease causing SNP). In particular, the present invention relates to engineered CRISPR/Cas systems comprising: a first Cas protein (e.g., Cas5-8 or Cas11) which is optionally tethered or fused to an effector protein selected from: i) an adenine deaminase, ii) a uracil glycosylase inhibitor, or iii) an APOBEC protein; and at least one guide RNA (gRNA) configured to hybridize to a portion of a target nucleic acid sequence. In certain embodiments, the systems further comprise a second Cas protein selected from: i) Cas3, ii) a helicase-deficient Cas3; or iii) a single-strand nicking Cas endonucleases (e.g., Cas9 Nickase H840A Protein).
Systems and methods for monitoring an international normalized ratio (INR) of a patient are disclosed. In some embodiments, INR data associated with the patient is received from an INR level measurement device. In some embodiments, a warfarin dosage recommendation is received, and the warfarin dosage recommendation is based on the INR data. In some embodiments, one or more user interfaces are presented on a display, and the one or more user interfaces comprise a user interface element indicating the warfarin dosage recommendation.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
72.
MODE DIVISION MULTIPLEXING USING COMBINED DEGENERATE MODES
An optical communication system can include a multiplexer/demultiplexer. The multiplexer/demultiplexer can transfer a first optical data signal between a first single-mode fiber and a first propagation mode of a few-mode fiber. The first propagation mode can have a first effective refractive index. The multiplexer/demultiplexer can transfer a second optical data signal between a second single-mode fiber and a combination of a second propagation mode of the few-mode fiber and a third propagation mode of the few-mode fiber. The second propagation mode and the third propagation mode can have a same effective refractive index that differs from the first effective refractive index. During propagation within the few-mode fiber, the second optical data signal can couple bidirectionally between the second propagation mode and the third propagation mode, while being substantially isolated from the first optical data signal in the first propagation mode.
G02B 6/28 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
73.
ATOMIC LAYER DEPOSITION PROCESS FOR FABRICATING DIELECTRIC METASURFACES FOR WAVELENGTHS IN THE VISIBLE SPECTRUM
A method of fabricating a visible spectrum optical component includes: providing a substrate; forming a resist layer over a surface of the substrate; patterning the resist layer to form a patterned resist layer defining openings exposing portions of the surface of the substrate; performing deposition to form a dielectric film over the patterned resist layer and over the exposed portions of the surface of the substrate, wherein a top surface of the dielectric film is above a top surface of the patterned resist layer; removing a top portion of the dielectric film to expose the top surface of the patterned resist layer and top surfaces of dielectric units within the openings of the patterned resist layer; and removing the patterned resist layer to retain the dielectric units over the substrate.
G02B 13/14 - Optical objectives specially designed for the purposes specified below for use with infrared or ultraviolet radiation
C23C 16/04 - Coating on selected surface areas, e.g. using masks
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
G02B 1/00 - Optical elements characterised by the material of which they are made; Optical coatings for optical elements
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
G03F 7/40 - Treatment after imagewise removal, e.g. baking
H01L 31/02 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof - Details
74.
METHODS FOR MULTI-FOCAL IMAGING FOR MOLECULAR PROFILING
The present disclosure generally relates to systems and methods for multi-focal imaging, for example, for determining nucleic acids in cells or other samples. In some cases, multiple focal planes may simultaneously be determined, e.g., by using a plurality of detectors, such as a plurality of cameras, which image the same sample, but at least some of which are focused on different focal planes within the sample. Thus, the sample may be imaged in 3 dimensions, e.g., without sample refocusing. In certain cases, this may improve the resolution of imaging, in space and/or time. Various embodiments can be used to increase imaging throughput and/or resolution in image-based approaches, e.g., for single-cell molecular profiling such as multiplexed error robust fluorescence in situ hybridization (MERFISH), or for other applications.
F03G 7/06 - Mechanical-power-producing mechanisms, not otherwise provided for or using energy sources not otherwise provided for using expansion or contraction of bodies due to heating, cooling, moistening, drying, or the like
F28D 17/04 - Distributing arrangements for the heat-exchange media
F28F 23/00 - Features relating to the use of intermediate heat-exchange materials, e.g. selection of compositions
F25B 23/00 - Machines, plants or systems, with a single mode of operation not covered by groups , e.g. using selective radiation effect
The present disclosure generally relates to evolved cytidine deaminases derived from cytidine deaminases, and methods of editing DNA using the same. In some aspects, the disclosure describes the directed evolution of a TadA-derived adenosine deaminase (TadA- CD) to perform cytidine deamination. In some embodiments, the TadA-CDs comprise a plurality of mutations compared to the parent TadA variant. In some embodiments, the TadA-CD is fused to a programmable DNA binding protein. Other aspects of the disclosure generally relate to a cytosine base editor (CBE) comprising a programmable DNA binding protein and the TadA-CD. In some embodiments, the disclosed cytosine base editor has improved efficiencies of conversion and reduced off-target editing frequencies compared to naturally-occurring CBEs. Also provided are polynucleotides, vectors, and kits useful for the generation and delivery of the CBEs. Cells containing such vectors and CBEs are also provided. Further provided are methods of treatment comprising administering the CBEs.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
77.
NOVEL SCREENING PLATFORM TO IDENTIFY IMMUNE MODULATORY AGENTS
A method of forming a three-dimensional structure includes forming a layer of resin comprising liquid crystal oligomers and a photoinitiator, applying a magnetic field to the formed layer in a predefined alignment direction for substantially aligning the liquid crystal oligomers in a first orientation; and exposing the formed layer to radiation for curing a first portion of the layer during application of the magnetic field thereby resulting in the first portion having liquid crystal elastomers substantially aligned in the first orientation. The method includes applying a second magnetic field to the formed layer in a predefined second alignment direction for substantially aligning uncured liquid crystal oligomers in a second orientation, and exposing the layer to radiation for curing a second portion of the layer during application of the second magnetic field thereby resulting in the second portion having liquid crystal elastomers substantially aligned in the second orientation.
B29C 64/188 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
Described herein are hematopoietic cell-specific targeting moieties and compositions including the hematopoietic cell specific targeting motifs. Also described herein are uses of the hematopoietic cell-specific targeting motifs and compositions including the hematopoietic cell specific targeting moieties. In some embodiments, the hematopoietic cell-specific targeting moieties and compositions including the hematopoietic cell specific targeting moieties can be used to direct delivery of a cargo to a hematopoietic cell.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The invention relates to the synthetic functionalization of an anthraquinone molecule that is substituted with at least one hydroxyl or amino group. In some aspects of the invention a mixture containing said anthraquinone starting material, an aldehyde, a base, an optional solvent, and an optional catalyst is reacted with hydrogen and then with an oxidant. In other aspects of the invention the synthetic functionalization of the anthraquinone molecule takes place electrochemically rather than chemically, through the use of a divided electrolytic cell.
Modified viral genomes are able to reduce induction of inflammatory and immune antiviral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.
Articles and devices comprising fluorinated elastomers, as well as methods of preparing fluorinated elastomers, are generally described. In some cases, such fluorinated elastomers can be used for sensing neural activity, e.g., by encapsulating electronic circuits, or other applications. Furthermore, according to certain embodiments, polymers can, surprisingly, be directly deposited onto layers comprising low molecular weight fluorinated elastomers, e.g., without swelling in the presence of certain solvents. Some embodiments are generally directed to devices and methods for treating fluorinated elastomers and subsequently depositing material onto the treated fluorinated elastomers. This may allow the fabrication and patterning of multilayered articles comprising fluorinated elastomers.
C08L 27/12 - Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment containing fluorine atoms
A61B 5/294 - Bioelectric electrodes therefor specially adapted for particular uses for nerve conduction study [NCS]
A61B 5/388 - Nerve conduction study, e.g. detecting action potential of peripheral nerves
A sensing probe may be formed of a diamond material comprising one or more spin defects that are configured to emit fluorescent light and are located no more than 50 nm from a sensing surface of the sensing probe. The sensing probe may include an optical outcoupling structure formed by the diamond material and configured to optically guide the fluorescent light toward an output end of the optical outcoupling structure. An optical detector may detect the fluorescent light that is emitted from the spin defects and that exits through the output end of the optical outcoupling structure after being optically guided therethrough. A mounting system may hold the sensing probe and control a distance between the sensing surface of the sensing probe and a surface of a sample while permitting relative motion between the sensing surface and the sample surface.
G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
G01R 33/032 - Measuring direction or magnitude of magnetic fields or magnetic flux using magneto-optic devices, e.g. Faraday
G01Q 60/54 - Probes, their manufacture or their related instrumentation, e.g. holders
G01R 33/12 - Measuring magnetic properties of articles or specimens of solids or fluids
G01R 33/60 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using electron paramagnetic resonance
The present disclosure relates to a method of inducing cellular rejuvenation and/or regeneration of a cell or tissue comprising contacting the cell with an effective amount of a protein or nucleic acid encoding a protein that induces cellular rejuvenation and/or regeneration of a cell or tissue. The present disclosure describes cell or tissue prepared according to methods described herein. The present disclosure also provides for methods of treating patients using cell or tissue generated by the methods described herein. The present disclosure also provides methods and systems for identifying a perturbant capable of changing a cell's state, function, and predicted age from an old reference state to a younger altered state.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The present disclosure provides methods of use of a particular GABA-A modulator compound, including in particular patient populations and/or for particular indications (e.g., diseases, disorders, or conditions).
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present disclosure relates to compositions and methods for detecting nucleic acid sequences (e.g., coding and non-coding RNAs; nuclear/genomic DNA; mtDNA; pathogen nucleic acids, etc.) in a tissue sample, specifically providing improved matrices and matrix-employing methods for performance of nucleic acid capture and amplification in a tissue sample in situ and/or in a manner that retains spatial location information for captured nucleic acids (including nucleic acid-associated macromolecules).
The present disclosure provides fusion proteins comprising a nanobody and a split glycosyl hydrolase enzyme. Also provided herein are split glycosyl hydrolase enzymes and fusion proteins comprising such enzymes. Further provided herein are polynucleotides, vectors, and cells. The present disclosure also provides methods of deglycosylating a protein and methods of studying the effects of glycosylation on protein function in cells. Also provided herein are methods of treating diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
88.
BATTERIES WITH SOLID STATE ELECTROLYTE MULTILAYERS
The invention provides rechargeable solid state batteries with multilayers of solid state electrolytes. The rechargeable solid state batteries disclosed herein are advantageous as they provide improved battery cycling performance combined with excellent power and energy density.
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
H01M 10/04 - Construction or manufacture in general
89.
BARCODING SYSTEMS AND METHODS FOR GENE SEQUENCING AND OTHER APPLICATIONS
The present invention generally relates to microfluidics and labeled nucleic acids. For example, certain aspects are generally directed to systems and methods for labeling nucleic acids within microfluidic droplets or other compartments, for instance, arising from a cell. In one set of embodiments, particles may be prepared containing oligonucleotides that can be used to determine target nucleic acids, e.g., attached to the surface of the particles. The oligonucleotides may include “barcodes” or unique sequences that can be used to distinguish nucleic acids in a droplet from those in another droplet, for instance, even after the nucleic acids are pooled together or removed from the droplets. Certain embodiments of the invention are generally directed to systems and methods for attaching additional or arbitrary sequences to the nucleic acids within microfluidic droplets or other compartments, e.g., recognition sequences that can be used to selectively determine or amplify a desired sequence suspected of being present within a droplet. Such systems may be useful, for example, for selective amplification in various applications, such as high-throughput sequencing applications.
A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Some aspects of this disclosure provide compositions, strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins capable of inducing a cytosine (C) to guanine (G) change in a nucleic acid (e.g., genomic DNA) are provided. In some embodiments, fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9) and nucleic acid editing proteins or protein domains, e.g., deaminase domains, polymerase domains, and/or base excision enzymes are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9), and nucleic acid editing proteins or domains, are provided.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/90 - Stable introduction of foreign DNA into chromosome
The technology described herein is directed to pharmaceutical compositions comprising at least one Scg2 neuropeptide, as well as cell culture media or kits comprising such Scg2 neuropeptides. Also described herein are nucleic acids, vectors, or viral vectors encoding at least one Scg2 neuropeptide. In further aspects, described herein are methods of treating a memory-associated disorder, a learning disability, a neurodegenerative disease or disorder, or epilepsy with a pharmaceutical composition, nucleic acid, vector, or viral vector as described herein. In further aspects, described herein are detection methods of memory-associated analytes, such as Scg2 neuropeptides.
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
94.
CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOF
Microbes expressing cholesterol oxidoreductase (COR) proteins, methods of engineering the microbes expressing COR proteins, compositions and methods of using the microbes are provided.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 9/00 - Medicinal preparations characterised by special physical form
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Provided herein are compositions and methods comprising engineered microorganisms and their use for locally degrading an antibiotic in the gastrointestinal tract to prevent or limit death of beneficial flora.
A photophoretically levitating macroscopic structure includes a photophoretically active structure (PAS), a PAS support framework, and a device superstructure. The photophoretically active structure includes at least one top sheet and at least one bottom sheet. The bottom sheet has greater solar-radiation absorptivity than the top surface, and each sheet defines a pattern of holes through which gas can flow. The sheets are separated by a gap that defines an open volume extending across a plurality of holes in each sheet. The photophoretically active structure is mounted in or on the PAS support framework. The device superstructure is mounted to and spans the PAS support framework to increase the rigidity of the photophoretically levitating macroscopic structure.
Topological qubits are provided in a quantum spin liquid. In various embodiments, a device is provided comprising a two-dimensional array of particles, each particle disposed at a vertex of a ruby lattice having a parameter ρ greater than
Topological qubits are provided in a quantum spin liquid. In various embodiments, a device is provided comprising a two-dimensional array of particles, each particle disposed at a vertex of a ruby lattice having a parameter ρ greater than
1
2
;
Topological qubits are provided in a quantum spin liquid. In various embodiments, a device is provided comprising a two-dimensional array of particles, each particle disposed at a vertex of a ruby lattice having a parameter ρ greater than
1
2
;
each particle having a first state and an excited state; each particle that belongs to at least three unit cells of the ruby lattice having a blockade radius, when in the excited state, sufficient to blockade each of at least six nearest neighboring particles in the ruby lattice from transitioning from its first state to its excited state, and wherein the array has at least one outer edge configured to be in a first boundary condition.
e.g., in situin situ, thereby providing multiple landing pads for labeled probes. The methods are well-suited to performance in multiplex, thereby permitting the sensitive detection of multiple targets in a single assay. These methods and compositions can be applied to, among other things, imaging, flow cytometry, CyTOF, and immunoblotting, providing additional tools for research and diagnostic purposes.
The methods, compositions and kits described herein provide signal amplification approaches for the detection of target biomolecules that significantly increase the sensitivity of detection using target-binding ligand molecules. The methods include cyclic addition of nucleic acid repeats to, e.g., target-binding molecules, thereby providing multiple landing pads for labeled probes. The methods are well-suited to performance in multiplex, thereby permitting the sensitive detection of multiple targets in a single assay. These methods and compositions can be applied to, among other things, imaging, flow cytometry, and mass cytometry/CyTOF, providing additional tools for research and diagnostic purposes.
A system is provided for embedding visualizations in a video stream of an athletic game based on a text relating thereto. The video stream may include a temporal sequence of video frames. The system may include a processor, a frame buffer for storing video stream comprising a temporal sequence of video frames. The system may also include an analysis module, executable by the processor, for analyzing the text to detect references therein to visualizable entities. The system may also include a mapping module, executable by the processor, for mapping the detected visualizable entities to visualizations. The system may also include an embedding module, executable by the processor, for embedding the generated visualizations in the video stream.
